Compare Equinor ASA (EQNR) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Humana Inc — how do they compare? Equinor ASA trades at $43.01 (market cap $101.62B), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Equinor ASA is far larger — about 2.2× Humana Inc's market cap, and Equinor ASA pays the higher dividend (3.63%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Humana Inc for 51 Days on average.
| EQNR | HUM | |
|---|---|---|
Market Cap | $101.62B | $46.49B |
Volume | 4,991,782 | 2,567,704 |
Sector | Energy | Health |
52-Week High | $45.75 | $409.85 |
52-Week Low | $22.41 | $163.67 |
Typical Hold Time | 59 Days | 51 Days |
Enterprise Value | $110.31B | $53.84B |
Dividend Yield | 3.63% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $42.93, up 3.17% today, with a bullish technical signal and strong valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $20.0 billion in 2025 and has announced dividends and share buy-backs, reflecting financial health.
The outlook is positive with a consensus price target of $87.50, implying significant upside. Key opportunities include LNG expansion plans and cost efficiency, while risks involve volatile energy prices and execution challenges. Analyst sentiment is mixed but leans bullish, supported by strong institutional interest and strategic growth initiatives.
Humana (HUM) trades at $387.12, down 2.37% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $457.05 implying 18% upside. Revenue growth is robust, reaching $129.7 billion in 2025, though net income margin has compressed to 0.88%. Recent news includes a Barclays upgrade to a $515 target and upcoming Q3 earnings on November 6, 2026.
The stock offers potential from strong revenue expansion and positive analyst sentiment, but faces risks from margin pressure and regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes. The outlook hinges on earnings performance and Medicare Advantage plan changes affecting membership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
